BG107896A - Състави на n-(метилетиламинокарбонил)-4-(3-метилфениламино)-3-пиридил-сулфона мид и циклични олигозахариди - Google Patents

Състави на n-(метилетиламинокарбонил)-4-(3-метилфениламино)-3-пиридил-сулфона мид и циклични олигозахариди Download PDF

Info

Publication number: BG107896A
Authority: BG; Bulgaria
Prior art keywords: cyclodextrin; torasemide; impurity; derivatives; alkyl
Prior art date: 2000-11-10

Application number

BG107896A

Other languages

Bulgarian (bg)

English (en)

Inventor

Miljenko Dumic

Darko Filic

Bozena Klepic

Aleksandar Danilovski

Marijan Tudja

Original Assignee

Pliva, Farmaceutska Industrija

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-10

Filing date

2003-06-10

Publication date

2004-01-30

2003-06-10 Application filed by Pliva, Farmaceutska Industrija filed Critical Pliva, Farmaceutska Industrija

2004-01-30 Publication of BG107896A publication Critical patent/BG107896A/bg

Links

-1 cyclic oligosaccharides Chemical class 0.000 title claims abstract description 31
239000000203 mixture Substances 0.000 title claims abstract description 17
229920001542 oligosaccharide Polymers 0.000 title abstract description 4
238000000034 method Methods 0.000 claims abstract description 23
238000002360 preparation method Methods 0.000 claims abstract description 20
229920000858 Cyclodextrin Polymers 0.000 claims description 126
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 65
229960005461 torasemide Drugs 0.000 claims description 63
230000004048 modification Effects 0.000 claims description 44
238000012986 modification Methods 0.000 claims description 44
229960004853 betadex Drugs 0.000 claims description 39
239000001116 FEMA 4028 Substances 0.000 claims description 37
229940097362 cyclodextrins Drugs 0.000 claims description 37
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 36
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 35
239000012535 impurity Substances 0.000 claims description 34
239000006069 physical mixture Substances 0.000 claims description 31
125000000217 alkyl group Chemical group 0.000 claims description 24
239000013543 active substance Substances 0.000 claims description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 13
239000000654 additive Substances 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 10
206010006451 bronchitis Diseases 0.000 claims description 8
150000002170 ethers Chemical class 0.000 claims description 8
238000004108 freeze drying Methods 0.000 claims description 8
208000028867 ischemia Diseases 0.000 claims description 8
239000002934 diuretic Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000001694 spray drying Methods 0.000 claims description 7
229940043377 alpha-cyclodextrin Drugs 0.000 claims description 6
230000001882 diuretic effect Effects 0.000 claims description 6
229920002678 cellulose Polymers 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 5
235000010980 cellulose Nutrition 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 5
239000000243 solution Substances 0.000 claims description 5
206010002383 Angina Pectoris Diseases 0.000 claims description 4
206010048962 Brain oedema Diseases 0.000 claims description 4
206010006458 Bronchitis chronic Diseases 0.000 claims description 4
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
206010020772 Hypertension Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
206010030113 Oedema Diseases 0.000 claims description 4
208000007536 Thrombosis Diseases 0.000 claims description 4
230000005856 abnormality Effects 0.000 claims description 4
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
208000006752 brain edema Diseases 0.000 claims description 4
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
230000000747 cardiac effect Effects 0.000 claims description 4
208000007451 chronic bronchitis Diseases 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
210000005003 heart tissue Anatomy 0.000 claims description 4
208000015181 infectious disease Diseases 0.000 claims description 4
208000014674 injury Diseases 0.000 claims description 4
230000004410 intraocular pressure Effects 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 4
230000002503 metabolic effect Effects 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
230000000451 tissue damage Effects 0.000 claims description 4
231100000827 tissue damage Toxicity 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
206010010254 Concussion Diseases 0.000 claims description 3
208000016998 Conn syndrome Diseases 0.000 claims description 3
206010027476 Metastases Diseases 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 3
206010037423 Pulmonary oedema Diseases 0.000 claims description 3
206010039808 Secondary aldosteronism Diseases 0.000 claims description 3
229920002472 Starch Polymers 0.000 claims description 3
239000000853 adhesive Substances 0.000 claims description 3
239000013566 allergen Substances 0.000 claims description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 3
235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
230000000181 anti-adherent effect Effects 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
230000009514 concussion Effects 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
235000019426 modified starch Nutrition 0.000 claims description 3
208000013846 primary aldosteronism Diseases 0.000 claims description 3
208000005333 pulmonary edema Diseases 0.000 claims description 3
230000009467 reduction Effects 0.000 claims description 3
239000007921 spray Substances 0.000 claims description 3
239000008107 starch Substances 0.000 claims description 3
235000019698 starch Nutrition 0.000 claims description 3
235000000346 sugar Nutrition 0.000 claims description 3
239000003826 tablet Substances 0.000 claims description 3
206010010904 Convulsion Diseases 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
210000004556 brain Anatomy 0.000 claims description 2
230000001037 epileptic effect Effects 0.000 claims description 2
239000004570 mortar (masonry) Substances 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
238000007738 vacuum evaporation Methods 0.000 claims description 2
229940080345 gamma-cyclodextrin Drugs 0.000 claims 5
208000003174 Brain Neoplasms Diseases 0.000 claims 2
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 2
238000001035 drying Methods 0.000 claims 2
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 2
206010059282 Metastases to central nervous system Diseases 0.000 claims 1
230000000172 allergic effect Effects 0.000 claims 1
208000010668 atopic eczema Diseases 0.000 claims 1
238000000265 homogenisation Methods 0.000 claims 1
238000001291 vacuum drying Methods 0.000 claims 1
235000011175 beta-cyclodextrine Nutrition 0.000 description 34
238000004090 dissolution Methods 0.000 description 15
238000002329 infrared spectrum Methods 0.000 description 12
239000000843 powder Substances 0.000 description 10
229960000965 nimesulide Drugs 0.000 description 8
HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 7
ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical group C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 7
229960004535 oxazepam Drugs 0.000 description 7
239000007787 solid Substances 0.000 description 7
230000000996 additive effect Effects 0.000 description 6
239000008247 solid mixture Substances 0.000 description 6
238000000113 differential scanning calorimetry Methods 0.000 description 4
238000001938 differential scanning calorimetry curve Methods 0.000 description 4
239000002904 solvent Substances 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000000227 grinding Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000126 substance Substances 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229960001259 diclofenac Drugs 0.000 description 2
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
229960001680 ibuprofen Drugs 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
229960001180 norfloxacin Drugs 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020571 Hyperaldosteronism Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000001857 anti-mycotic effect Effects 0.000 description 1
239000002543 antimycotic Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
229960004988 azosemide Drugs 0.000 description 1
229960002206 bifonazole Drugs 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
229960004064 bumetanide Drugs 0.000 description 1
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229950008138 carmellose Drugs 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
229960004590 diacerein Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
229960004580 glibenclamide Drugs 0.000 description 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
229960003642 nicergoline Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000000590 phytopharmaceutical Substances 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960000351 terfenadine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Medical Informatics (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

BG107896A 2000-11-10 2003-06-10 Състави на n-(метилетиламинокарбонил)-4-(3-метилфениламино)-3-пиридил-сулфона мид и циклични олигозахариди BG107896A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HR20000765A HRP20000765A2 (en)	2000-11-10	2000-11-10	Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
PCT/HR2001/000004 WO2002038186A1 (en)	2000-11-10	2001-01-31	Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides

Publications (1)

Publication Number	Publication Date
BG107896A true BG107896A (bg)	2004-01-30

Family

ID=10947206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG107896A BG107896A (bg)	2000-11-10	2003-06-10	Състави на n-(метилетиламинокарбонил)-4-(3-метилфениламино)-3-пиридил-сулфона мид и циклични олигозахариди

Country Status (26)

Country	Link
US (1)	US7037928B2 (et)
EP (1)	EP1347780B1 (et)
JP (1)	JP2004513155A (et)
KR (1)	KR20030060929A (et)
CN (1)	CN1477977A (et)
AR (1)	AR026815A1 (et)
AU (1)	AU2001228721A1 (et)
BG (1)	BG107896A (et)
BR (1)	BR0115281A (et)
CA (1)	CA2428179A1 (et)
CZ (1)	CZ20031490A3 (et)
DE (1)	DE60125828T2 (et)
EA (1)	EA005111B1 (et)
EE (1)	EE200300197A (et)
GE (1)	GEP20043403B (et)
HR (1)	HRP20000765A2 (et)
HU (1)	HUP0400776A2 (et)
IL (1)	IL155818A0 (et)
IS (1)	IS6810A (et)
MX (1)	MXPA03004111A (et)
NO (1)	NO20032091L (et)
PL (1)	PL361667A1 (et)
SK (1)	SK6722003A3 (et)
WO (1)	WO2002038186A1 (et)
YU (1)	YU35303A (et)
ZA (1)	ZA200303601B (et)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI21703A (en) *	2004-01-14	2005-08-31	Lek Farmacevtska Druzba Dd	Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
ATE375977T1 (de) *	2004-01-22	2007-11-15	Pfizer	Sulfonamidderivate zur behandlung von krankheiten
CN100372534C (zh) *	2006-04-20	2008-03-05	南京海辰药业有限公司	托拉塞米冻干制剂及制备方法
JP5469595B2 (ja)	2007-04-13	2014-04-16	ミレニアムファーマシューティカルズ，インコーポレイテッド	第Ｘａ因子阻害薬として作用する化合物との併用抗凝固療法
BR102012009317B1 (pt) *	2012-04-20	2022-05-31	Universidade Federal De Minas Gerais - Ufmg	Processo de preparação de compostos de inclusão envolvendo ciclodextrinas e fármacos, usando um sistema de fluxo contínuo
JP6837190B2 (ja) *	2015-06-16	2021-03-03	エイティーエックスエーセラピューティクスリミテッド	トロンボキサン受容体アンタゴニスト
EP3893843B1 (en)	2018-12-10	2025-07-30	SQ Innovation AG	Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en)	2019-01-04	2022-02-15	Sq Innovation Ag	Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en)	2019-01-04	2025-08-26	Sq Innovation Ag	Pharmaceutical compositions of torsemide and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US576511A (en) *		1897-02-02		Georg steinike and friedrich schmidt
DE3529529A1 (de) *	1985-08-17	1987-02-19	Boehringer Mannheim Gmbh	Verfahren zur herstellung einer stabilen modifikation von torasemid
KR100485459B1 (ko) *	1995-12-01	2005-08-31	코닌클리케 필립스 일렉트로닉스 엔.브이.	디지탈무선전화시스템,무선기지국,및무선기지국과무선핸드셋을포함하는무선전화시스템
US6828334B2 (en) *	2002-05-23	2004-12-07	Usv Limited	Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition

2000
- 2000-11-10 HR HR20000765A patent/HRP20000765A2/hr not_active Application Discontinuation
2001
- 2001-01-09 AR ARP010100079A patent/AR026815A1/es not_active Application Discontinuation
- 2001-01-31 PL PL01361667A patent/PL361667A1/xx unknown
- 2001-01-31 CA CA002428179A patent/CA2428179A1/en not_active Abandoned
- 2001-01-31 IL IL15581801A patent/IL155818A0/xx unknown
- 2001-01-31 EE EEP200300197A patent/EE200300197A/et unknown
- 2001-01-31 CN CNA018198309A patent/CN1477977A/zh active Pending
- 2001-01-31 SK SK672-2003A patent/SK6722003A3/sk unknown
- 2001-01-31 BR BR0115281-5A patent/BR0115281A/pt not_active IP Right Cessation
- 2001-01-31 KR KR10-2003-7006357A patent/KR20030060929A/ko not_active Withdrawn
- 2001-01-31 DE DE60125828T patent/DE60125828T2/de not_active Expired - Fee Related
- 2001-01-31 WO PCT/HR2001/000004 patent/WO2002038186A1/en not_active Ceased
- 2001-01-31 MX MXPA03004111A patent/MXPA03004111A/es unknown
- 2001-01-31 EA EA200300556A patent/EA005111B1/ru not_active IP Right Cessation
- 2001-01-31 HU HU0400776A patent/HUP0400776A2/hu unknown
- 2001-01-31 JP JP2002540768A patent/JP2004513155A/ja active Pending
- 2001-01-31 GE GE5156A patent/GEP20043403B/en unknown
- 2001-01-31 US US10/416,303 patent/US7037928B2/en not_active Expired - Fee Related
- 2001-01-31 ZA ZA200303601A patent/ZA200303601B/xx unknown
- 2001-01-31 EP EP01993478A patent/EP1347780B1/en not_active Expired - Lifetime
- 2001-01-31 AU AU2001228721A patent/AU2001228721A1/en not_active Abandoned
- 2001-01-31 YU YU35303A patent/YU35303A/sh unknown
- 2001-01-31 CZ CZ20031490A patent/CZ20031490A3/cs unknown
2003
- 2003-05-08 IS IS6810A patent/IS6810A/is unknown
- 2003-05-09 NO NO20032091A patent/NO20032091L/no not_active Application Discontinuation
- 2003-06-10 BG BG107896A patent/BG107896A/bg unknown

Also Published As

Publication number	Publication date
AU2001228721A1 (en)	2002-05-21
EP1347780B1 (en)	2007-01-03
CZ20031490A3 (cs)	2003-08-13
JP2004513155A (ja)	2004-04-30
HRP20000765A2 (en)	2002-06-30
US7037928B2 (en)	2006-05-02
PL361667A1 (en)	2004-10-04
EA200300556A1 (ru)	2003-08-28
DE60125828T2 (de)	2007-08-16
GEP20043403B (en)	2004-06-10
HUP0400776A2 (hu)	2004-08-30
YU35303A (sh)	2006-03-03
BR0115281A (pt)	2003-07-29
DE60125828D1 (de)	2007-02-15
EE200300197A (et)	2003-08-15
MXPA03004111A (es)	2004-05-05
WO2002038186A1 (en)	2002-05-16
NO20032091L (no)	2003-07-02
EP1347780A1 (en)	2003-10-01
IL155818A0 (en)	2003-12-23
IS6810A (is)	2003-05-08
US20040039204A1 (en)	2004-02-26
SK6722003A3 (en)	2003-10-07
EA005111B1 (ru)	2004-10-28
CN1477977A (zh)	2004-02-25
CA2428179A1 (en)	2002-05-16
NO20032091D0 (no)	2003-05-09
ZA200303601B (en)	2004-07-19
AR026815A1 (es)	2003-02-26
KR20030060929A (ko)	2003-07-16

Publication	Publication Date	Title
EP3437637B1 (en)	2023-12-20	Pharmaceutical preparation of palbociclib and medical use thereof
KR100349754B1 (ko)	2002-12-18	제약조성물
WO2014161131A1 (en)	2014-10-09	PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
US20110009362A1 (en)	2011-01-13	Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
WO2003095498A1 (en)	2003-11-20	Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
US20110177161A1 (en)	2011-07-21	Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
JP3693341B2 (ja)	2005-09-07	タキソールまたはタキソテレまたはイチイ抽出物と、シクロデキストリンとから成る封入複合体、該複合体の製造及び使用
PL189324B1 (pl)	2005-07-29	Środek farmaceutyczny i nowe sole zyprazydonu
US10894049B2 (en)	2021-01-19	Pharmaceutical formulation of palbociclib and a preparation method thereof
JP6641062B2 (ja)	2020-02-05	テコビリマットの経口用医薬組成物及びその調製法
BG107896A (bg)	2004-01-30	Състави на n-(метилетиламинокарбонил)-4-(3-метилфениламино)-3-пиридил-сулфона мид и циклични олигозахариди
EP0295476A2 (en)	1988-12-21	Inclusion complexes of dipyridamole with cyclodextrins
JP2008524393A (ja)	2008-07-10	ポリアルコキシスルホネート表面改変因子
ES2206254T3 (es)	2004-05-16	Complejos de paroxetina con ciclodextrinas o derivados de ciclodextrinas.
NO314438B1 (no)	2003-03-24	Estramustin formuleringer med forbedrede farmasöytiske egenskaper, samt anvendelse derav
JP2004531525A (ja)	2004-10-14	アニリドとシクロデキストリンとの複合体、その製造および特に異常脂肪血症の治療のための医薬としてのその使用
Patil et al.	2009	Studies on Occlusion Complexes of Aceclofenac with β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin
HK40004093A (en)	2020-04-24	Pharmaceutical preparation of palbociclib and preparation method thereof
WO2009007996A2 (en)	2009-01-15	Cyclodextrin complexes of atovaquone